Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Brief Communication
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 February 2018
|
| In: |
Leukemia
Year: 2018, Jahrgang: 32, Heft: 8, Pages: 1799-1803 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/s41375-018-0023-2 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1038/s41375-018-0023-2 Verlag, Volltext: https://www.nature.com/articles/s41375-018-0023-2 
|
| Verfasserangaben: | S. Rule, W. Jurczak, M. Jerkeman, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, S.-G. Cho, C. Thieblemont, W. Zhou, T. Henninger, J. Goldberg, J. Vermeulen, M. Dreyling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1663771448 | ||
| 003 | DE-627 | ||
| 005 | 20220816142922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190430s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-018-0023-2 |2 doi | |
| 035 | |a (DE-627)1663771448 | ||
| 035 | |a (DE-599)KXP1663771448 | ||
| 035 | |a (OCoLC)1341211858 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rule, Simon |e VerfasserIn |0 (DE-588)118491818X |0 (DE-627)1663770697 |4 aut | |
| 245 | 1 | 0 | |a Ibrutinib versus temsirolimus |b 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |c S. Rule, W. Jurczak, M. Jerkeman, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, S.-G. Cho, C. Thieblemont, W. Zhou, T. Henninger, J. Goldberg, J. Vermeulen, M. Dreyling |
| 264 | 1 | |c 2 February 2018 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.04.2019 | ||
| 520 | |a Brief Communication | ||
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 32(2018), 8, Seite 1799-1803 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Ibrutinib versus temsirolimus 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:8 |g pages:1799-1803 |g extent:5 |a Ibrutinib versus temsirolimus 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41375-018-0023-2 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41375-018-0023-2 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190430 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1663771448 |e 3456361076 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 30.04.2019"],"recId":"1663771448","language":["eng"],"person":[{"role":"aut","display":"Rule, Simon","roleDisplay":"VerfasserIn","given":"Simon","family":"Rule"},{"family":"Witzens-Harig","given":"Mathias","display":"Witzens-Harig, Mathias","roleDisplay":"VerfasserIn","role":"aut"}],"title":[{"subtitle":"3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","title":"Ibrutinib versus temsirolimus","title_sort":"Ibrutinib versus temsirolimus"}],"physDesc":[{"extent":"5 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group"}],"id":{"eki":["32046699X"],"zdb":["2008023-2"],"issn":["1476-5551"]},"disp":"Ibrutinib versus temsirolimus 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY studyLeukemia","note":["Gesehen am 15.03.04"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"32046699X","pubHistory":["Nachgewiesen 11.1997 -"],"part":{"extent":"5","volume":"32","text":"32(2018), 8, Seite 1799-1803","issue":"8","pages":"1799-1803","year":"2018"},"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia","title_sort":"Leukemia"}]}],"name":{"displayForm":["S. Rule, W. Jurczak, M. Jerkeman, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, S.-G. Cho, C. Thieblemont, W. Zhou, T. Henninger, J. Goldberg, J. Vermeulen, M. Dreyling"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2 February 2018"}],"id":{"eki":["1663771448"],"doi":["10.1038/s41375-018-0023-2"]}} | ||
| SRT | |a RULESIMONWIBRUTINIBV2201 | ||